Please use this identifier to cite or link to this item:
10.1186/s13053-022-00209-1
Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Maksimenko, Jeļena | - |
| dc.contributor.author | Irmejs, Arvīds | - |
| dc.contributor.author | Gardovskis, Jānis | - |
| dc.date.accessioned | 2022-01-27T20:25:01Z | - |
| dc.date.available | 2022-01-27T20:25:01Z | - |
| dc.date.issued | 2022-01-21 | - |
| dc.identifier.citation | Maksimenko , J , Irmejs , A & Gardovskis , J 2022 , ' Pregnancy after breast cancer in BRCA1/2 mutation carriers ' , Hereditary Cancer in Clinical Practice , vol. 20 , no. 1 , 3 , pp. 3 . https://doi.org/10.1186/s13053-022-00209-1 , https://doi.org/10.1186/s13053-022-00209-1 | - |
| dc.identifier.issn | 1731-2302 | - |
| dc.identifier.other | Mendeley: 7d2f43e6-6888-3faf-a321-0131002e4dc2 | - |
| dc.identifier.other | PubMedCentral: PMC8781048 | - |
| dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/7339 | - |
| dc.description | Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)?Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme ?ERN-2016?Framework Partnership Agreement 2017?2021. Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme “ERN-2016—Framework Partnership Agreement 2017–2021. Publisher Copyright: © 2022, The Author(s). | - |
| dc.description.abstract | Background: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. Methods: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. Main body of the abstract: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. Conclusion: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients’ needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment. | en |
| dc.format.extent | 7 | - |
| dc.format.extent | 606639 | - |
| dc.language.iso | eng | - |
| dc.relation.ispartof | Hereditary Cancer in Clinical Practice | - |
| dc.rights | info:eu-repo/semantics/openAccess | - |
| dc.subject | 3.1 Basic medicine | - |
| dc.subject | 3.2 Clinical medicine | - |
| dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
| dc.subject | SDG 3 - Good Health and Well-being | - |
| dc.title | Pregnancy after breast cancer in BRCA1/2 mutation carriers | en |
| dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/systematicreview | - |
| dc.identifier.doi | 10.1186/s13053-022-00209-1 | - |
| dc.contributor.institution | Department of Surgery | - |
| dc.contributor.institution | RSU Institute of Oncology | - |
| dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85123345262&partnerID=8YFLogxK | - |
| dc.description.status | Peer reviewed | - |
| Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| Pregnancy_after_breast_cancer_in.pdf | 592.42 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.